BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 24295076)

  • 21. Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy.
    Bojarsky M; Baran JA; Halada S; Isaza A; Zhuang H; States L; Grant FD; Robbins S; Sisko L; Ricarte-Filho JC; Kazahaya K; Adzick NS; Mostoufi-Moab S; Bauer AJ
    J Clin Endocrinol Metab; 2023 Nov; 108(12):3338-3344. PubMed ID: 37265226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
    Patel SS; Goldfarb M
    J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
    Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
    Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
    Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
    J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary iodine excretion after contrast computed tomography scan: implications for radioactive iodine use.
    Nimmons GL; Funk GF; Graham MM; Pagedar NA
    JAMA Otolaryngol Head Neck Surg; 2013 May; 139(5):479-82. PubMed ID: 23599025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic 123I and 131I activities and radioiodine therapy. Effects on urinary iodine excretion in patients with differentiated thyroid carcinoma.
    Meller B; von Hof K; Genina E; Deisting W; Meller J; Richter E; Baehre M
    Nuklearmedizin; 2005; 44(6):243-8. PubMed ID: 16400384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare.
    Marti JL; Davies L; Haymart MR; Roman BR; Tuttle RM; Morris LG
    Thyroid; 2015 Jul; 25(7):865-6. PubMed ID: 25963001
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
    Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
    Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z; Flores J; Katz S; Nathan CA; Mehta V
    Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer.
    Sun Y; Sun Q; Tian J; He X
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1413-e1423. PubMed ID: 37167097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma.
    Shi ZY; Zhang SX; Fan D; Li CH; Cheng ZH; Xue Y; Wu LX; Lu KY; Yang SY; Cheng Y; Wu ZF; Gao C; Li XF; Liu HY; Li SJ
    Front Immunol; 2022; 13():901263. PubMed ID: 35844520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
    Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
    Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients.
    Tala Jury HP; Castagna MG; Fioravanti C; Cipri C; Brianzoni E; Pacini F
    J Clin Endocrinol Metab; 2010 Jan; 95(1):230-7. PubMed ID: 19858316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.
    Kusacic Kuna S; Samardzic T; Tesic V; Medvedec M; Kuna K; Bracic I; Despot M; Dodig D
    Nucl Med Commun; 2009 Apr; 30(4):263-9. PubMed ID: 19247212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
    Sacks W; Wong RM; Bresee C; Braunstein GD
    Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
    Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
    Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.